Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy

Intern Med. 2021 Jan 15;60(2):251-257. doi: 10.2169/internalmedicine.5499-20. Epub 2020 Sep 19.

Abstract

We herein describe an 82-year-old patient who presented with proteinuria and systemic edema. He was diagnosed with minimal change disease (MCD) and was found to have stage III pancreatic cancer. He could not undergo surgical resection due to invasion to the celiac artery and he was thus treated with chemotherapy. After a month of chemotherapy, his proteinuria improved to a normal level. After two months of chemotherapy, computed tomography indicated a partial response to the therapy. MCD can occur as paraneoplastic syndrome in patients with malignant disease, and chemotherapy can be effective for MCD associated with paraneoplastic syndrome.

Keywords: chemoradiotherapy; minimal change disease; nab-Paclitaxel; pancreatic cancer; proteinuria.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Albumins / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Deoxycytidine / therapeutic use
  • Humans
  • Male
  • Nephrosis, Lipoid* / complications
  • Nephrosis, Lipoid* / drug therapy
  • Paclitaxel / therapeutic use
  • Pancreatic Neoplasms* / complications
  • Pancreatic Neoplasms* / drug therapy

Substances

  • Albumins
  • Deoxycytidine
  • Paclitaxel